Oxycodone-naltrexone: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 281 patients with moderate to severe chronic low back pain showed that ALO-02 met the primary endpoint of improving

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE